Canakinumab For The Treatment of Amyloidosis Secondary to Lung Cancer
Amyloidosis and Canakinumab
Abstract views: 83
/ 
PDF downloads: 51
DOI:
https://doi.org/10.5281/zenodo.8134945Keywords:
Amyloidosis, canakinumab, inflammation, Small cell lung cancer, proteinuriaAbstract
AA amyloidosis is a disease that occurs with the accumulation of Serum Amyloid A protein due to chronic inflammatory processes. Malignancies are an infrequent cause of secondary amyloidosis; therefore, there is not much data on the treatment of amyloidosis in these patients. We present a 62-year-old male patient who was diagnosed with AA amyloidosis secondary to lung squamous cell carcinoma and successfully treated with canakinumab. Ramipril was started for the patient because of the 2 gram/day proteinuria at the time of lung cancer diagnosis. However, in the follow-ups, the proteinuria increased to 10 g/day, and the kidney biopsy was compatible with amyloidosis. Canakinumab (150 mg every 28 days) treatment was started, and proteinuria regressed below 1 g/day in 3 months. As the role of IL 1 in malignant diseases has become clear, data have emerged suggesting that treatments reducing IL 1 activity may be a treatment option in these diseases. There is no data on the use of canakinumab in treating amyloidosis secondary to solid organ tumors, and we present this usage for the first time with this case report.
References
Hazenberg BPC. Amyloidosis: A Clinical Overview. Rheum Dis Clin North Am. 2013 May 1;39(2):323–45. https://doi.org/10.1016/j.rdc.2013.02.012
Migita K, Koga T, Satomura K, Izumi M, Torigoshi T, Maeda Y, et al. Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts. Arthritis Res Ther. 2012 May 18;14(3):1–8. https://arthritis-research.biomedcentral.com/articles/10.1186/ar3849
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018 May 17;378(20):1908–19. https://pubmed.ncbi.nlm.nih.gov/29768139/
Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019 Mar 4;29(2):363–6. https://pubmed.ncbi.nlm.nih.gov/29578360/
Pretre V, Papadopoulos D, Regard J, Pelletier M, Woo J. Interleukin-1 (IL-1) and the inflammasome in cancer. Cytokine. 2022 May 1;153:155850. https://doi.org/10.1016/j.cyto.2022.155850
Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021 218. 2021 Jun 3;21(8):481–99. https://www.nature.com/articles/s41568-021-00363-z
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119–31. https://pubmed.ncbi.nlm.nih.gov/28845751/
Ridker PM, MacFadyen JG, Thuren T, Everett B, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21;390(10105):1833–42. Available from: https://pubmed.ncbi.nlm.nih.gov/28855077/
Lythgoe, M.P., Prasad, V. Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology. Br J Cancer 127, 785–787 (2022). https://doi.org/10.1038/s41416-022-01893-5.
Paz-Ares L, Goto Y, Lim WDT, Halmos B, Cho BC, Dols MC, et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann Oncol. 2021;32:S953–4.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Journal of European Internal Medicine Professionals
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 